Aliases & Classifications for Aphasia

MalaCards integrated aliases for Aphasia:

Name: Aphasia 12 54 55 6 43 44 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:0060046
MeSH 44 D001037
UMLS 72 C0003537

Summaries for Aphasia

NINDS : 54 Aphasia is a neurological disorder caused by damage to the portions of the brain that are responsible for language production or processing.  It may occur suddenly or progressively, depending on the type and location of brain tissue involved.  Primary signs of the disorder include difficulty in expressing oneself when speaking, trouble understanding speech, and difficulty with reading and writing. Aphasia is not a disease, but a symptom of brain damage. Although it is primarily seen in individuals who have suffered a stroke, aphasia can also result from a brain tumor, infection, inflammation, head injury, or dementia that affect language-associated regions of the brain. It is estimated that about 1 million people in the United States today suffer from aphasia. The type and severity of language dysfunction depends on the precise location and extent of the damaged brain tissue. Generally, aphasia can be divided into four broad categories: (1) Expressive aphasia (also called Broca's aphasia) involves difficulty in conveying thoughts through speech or writing. The person knows what she/he wants to say, but cannot find the words he needs. (2) Receptive aphasia (Wernicke's aphasia) involves difficulty understanding spoken or written language. The individual hears the voice or sees the print but cannot make sense of the words. (3) Global aphasia results from severe and extensive damage to the language areas of the brain.  People lose almost all language function, both comprehension and expression. They cannot speak or understand speech, nor can they read or write.  (4) Indiivfduals with anomic or amnesia aphasia, the least severe form of aphasia, have difficulty in using the correct names for particular objects, people, places, or events.

MalaCards based summary : Aphasia is related to frontotemporal lobar degeneration with tdp43 inclusions, grn-related and epilepsy-aphasia spectrum, and has symptoms including seizures, tremor and fever. An important gene associated with Aphasia is L1CAM (L1 Cell Adhesion Molecule), and among its related pathways/superpathways are Neuroscience and Reelin Pathway (Cajal-Retzius cells). The drugs Carbidopa and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 A language disorder that involves an acquired impairment of any laguage modality such as producting or comprehending spoken or written language.

MedlinePlus : 43 Aphasia is a disorder caused by damage to the parts of the brain that control language. It can make it hard for you to read, write, and say what you mean to say. It is most common in adults who have had a stroke. Brain tumors, infections, injuries, and dementia can also cause it. The type of problem you have and how bad it is depends on which part of your brain is damaged and how much damage there is. There are four main types: Expressive aphasia - you know what you want to say, but you have trouble saying or writing what you mean Receptive aphasia - you hear the voice or see the print, but you can't make sense of the words Anomic aphasia - you have trouble using the correct word for objects, places, or events Global aphasia - you can't speak, understand speech, read, or write Some people recover from aphasia without treatment. Most, however, need language therapy as soon as possible. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 75 Aphasia is an inability to comprehend or formulate language because of damage to specific brain regions.... more...

Related Diseases for Aphasia

Diseases related to Aphasia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 436, show less)
# Related Disease Score Top Affiliating Genes
1 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 34.7 MAPT GRN
2 epilepsy-aphasia spectrum 34.5 GRIN2A CNKSR2
3 progressive non-fluent aphasia 33.8 PSEN1 MAPT GRN CHMP2B C9orf72
4 nominal aphasia 33.8 TARDBP PSEN1 MAPT GRN CHMP2B
5 supranuclear palsy, progressive, 1 32.3 MAPT GRN APP APOE
6 agraphia 32.0 TARDBP PSEN1 PRNP MAPT GRN
7 semantic dementia 32.0 TARDBP PSEN1 MAPT GRN CHMP2B C9orf72
8 pick disease of brain 31.8 TARDBP PSEN1 MAPT GRN APP APOE
9 ideomotor apraxia 31.5 MAPT GRN
10 mutism 31.4 GRN CHMP2B
11 apraxia 31.4 PSEN1 MAPT GRN FOXP2 C9orf72
12 cerebrovascular disease 31.3 MAPT APP APOE
13 echolalia 31.2 PSEN1 MAPT GRN
14 alexia 31.1 TARDBP PSEN1 APOE
15 posterior cortical atrophy 30.9 MAPT APOE
16 prosopagnosia 30.9 PSEN1 GRN
17 visual agnosia 30.9 PSEN1 GRN
18 creutzfeldt-jakob disease 30.9 PRNP MAPT APOE
19 speech disorder 30.7 GRN GRIN2A FOXP2
20 associative agnosia 30.6 TARDBP PSEN1 GRN
21 akinetic mutism 30.6 PRNP MAPT
22 behavioral variant of frontotemporal dementia 30.6 PSEN1 MAPT GRN CHMP2B C9orf72
23 lateral sclerosis 30.5 TBK1 TARDBP C9orf72
24 prion disease 30.5 PRNP MAPT APP
25 kluver-bucy syndrome 30.5 PSEN1 MAPT APP
26 simultanagnosia 30.4 MAPT APOE
27 leukoencephalopathy, hereditary diffuse, with spheroids 30.0 PRNP MAPT APP
28 frontotemporal dementia 30.0 TBK1 TARDBP PSEN1 PRNP MAPT GRN
29 phonagnosia 30.0 TARDBP PSEN1 GRN
30 writing disorder 30.0 TARDBP PSEN1 GRN
31 motor neuron disease 29.9 TBK1 TARDBP MAPT GRN C9orf72
32 hydrocephalus 29.9 MAPT L1CAM APP APOE
33 vascular dementia 29.9 PSEN1 MAPT APP APOE
34 early-onset, autosomal dominant alzheimer disease 29.7 TOMM40 PSEN1 APP
35 amyloidosis 29.7 PSEN1 APP APOE
36 gait apraxia 29.7 PSEN1 GRN APP APOE
37 hydrocephalus, normal-pressure 29.5 MAPT APOE
38 alzheimer disease 29.4 TARDBP PSEN1 PRNP MAPT GRN GRIN2A
39 cerebral amyloid angiopathy, cst3-related 29.3 PSEN1 PRNP MAPT APP APOE
40 benign epilepsy with centrotemporal spikes 29.2 SRPX2 GRIN2A FOXP2
41 dementia 28.3 TBK1 TARDBP PSEN1 PRNP MAPT GRN
42 speech and communication disorders 28.3 TARDBP PSEN1 MAPT L1CAM GRN GRIN2A
43 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 28.2 TBK1 TARDBP PSEN1 MAPT GRN CHMP2B
44 amyotrophic lateral sclerosis 1 28.2 TBK1 TARDBP PSEN1 PRNP MAPT GRN
45 logopenic progressive aphasia 12.7
46 epilepsy, focal, with speech disorder and with or without mental retardation 12.3
47 landau-kleffner syndrome 12.3
48 progressive supranuclear palsy-progressive non-fluent aphasia syndrome 12.3
49 masa syndrome 12.2
50 intellectual disability-expressive aphasia-facial dysmorphism syndrome 12.2
51 gerstmann syndrome 11.9
52 cerebral atrophy 11.7
53 spastic paraplegia 1 11.5
54 grn-related frontotemporal dementia 11.4
55 moyamoya disease 1 11.4
56 frontotemporal dementia, chromosome 3-linked 11.4
57 progressive multifocal leukoencephalopathy 11.4
58 marchiafava bignami disease 11.4
59 autosomal dominant partial epilepsy with auditory features 11.2
60 sudanophilic cerebral sclerosis 11.1
61 handl syndrome 11.1
62 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 11.1
63 spastic paraplegia 16 11.1
64 x-linked charcot-marie-tooth disease 11.1
65 chmp2b-related frontotemporal dementia 11.1
66 myelinoclastic diffuse sclerosis 11.1
67 stroke, ischemic 10.8
68 hemiplegia 10.7
69 dysgraphia 10.7
70 agnosia 10.7
71 corticobasal degeneration 10.6
72 hand skill, relative 10.6
73 genetic prion diseases 10.5 PRNP APOE
74 epilepsy 10.5
75 dyslexia 10.5
76 alzheimer disease 4 10.5 PSEN1 APOE
77 branchiootic syndrome 1 10.5
78 cognitive impairment with or without cerebellar ataxia 10.5
79 status epilepticus 10.5
80 encephalitis 10.5
81 specific language disorder 10.5
82 senile plaque formation 10.5 APP APOE
83 seizure disorder 10.4
84 visual epilepsy 10.4
85 alzheimer's disease 1 10.4 APP APOE
86 auditory agnosia 10.4
87 amnestic disorder 10.4
88 encephalopathy 10.3
89 traumatic brain injury 10.3
90 huntington disease-like 1 10.3 PRNP APOE
91 anosognosia 10.3
92 stuttering 10.3
93 head injury 10.3
94 alzheimer disease mitochondrial 10.3 MAPT APP APOE
95 binswanger's disease 10.3 MAPT APP APOE
96 multiple sclerosis 10.3
97 ataxia and polyneuropathy, adult-onset 10.3
98 postencephalitic parkinson disease 10.3 TARDBP MAPT
99 rolandic epilepsy-speech dyspraxia syndrome 10.2 SRPX2 GRIN2A
100 migraine with or without aura 1 10.2
101 pica disease 10.2
102 dysphagia 10.2
103 arteriolosclerosis 10.2 TARDBP APOE
104 toxic encephalopathy 10.2 PRNP GRIN2A APP
105 ocular motor apraxia 10.2
106 yemenite deaf-blind hypopigmentation syndrome 10.2
107 focal epilepsy 10.2
108 depression 10.2
109 meningioma, radiation-induced 10.2
110 meningioma, familial 10.2
111 spinal meningioma 10.2
112 secretory meningioma 10.2
113 lymphoplasmacyte-rich meningioma 10.2
114 headache 10.2
115 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.2
116 amusia 10.2
117 arteriovenous malformation 10.2
118 herpes simplex 10.2
119 brain injury 10.2
120 anxiety 10.1
121 transient cerebral ischemia 10.1
122 temporal lobe epilepsy 10.1
123 meningitis 10.1
124 herpes simplex encephalitis 10.1
125 myoclonus 10.1
126 tremor 10.1
127 primary progressive apraxia of speech 10.1
128 amyotrophic lateral sclerosis 18 10.1 TARDBP C9orf72
129 communicating hydrocephalus 10.1 MAPT APOE
130 pulmonary alveolar microlithiasis 10.1
131 facial paralysis 10.1
132 glioblastoma multiforme 10.1
133 astrocytoma 10.1
134 intracranial embolism 10.1
135 dystonia 10.1
136 vasculitis 10.1
137 learning disability 10.1
138 glioblastoma 10.1
139 kohlschutter-tonz syndrome 10.1 PSEN1 MAPT APP APOE
140 autism 10.1
141 gastrointestinal stromal tumor 10.1
142 verbal auditory agnosia 10.1
143 endocarditis 10.1
144 meningoencephalitis 10.1
145 dyscalculia 10.1
146 reading disorder 10.1
147 subacute delirium 10.1
148 47,xyy 10.1
149 supranuclear ocular palsy 10.1
150 alzheimer disease 2 10.1 PSEN1 MAPT APP APOE
151 perry syndrome 10.1 TARDBP GRN C9orf72
152 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
153 aging 10.0
154 finger agnosia 10.0
155 typhoid fever 10.0
156 ischemia 10.0
157 middle cerebral artery infarction 10.0
158 intracranial thrombosis 10.0
159 movement disease 10.0
160 grin2a-related speech disorders and epilepsy 10.0
161 foix chavany marie syndrome 10.0
162 febrile seizures 10.0
163 rare surgical neurologic disease 10.0
164 progressive muscular atrophy 10.0 TARDBP C9orf72
165 beta-amino acids, renal transport of 10.0
166 schizophrenia 10.0
167 uruguay faciocardiomusculoskeletal syndrome 10.0
168 dysphasia, familial developmental 10.0
169 aceruloplasminemia 10.0
170 primary lateral sclerosis, adult, 1 10.0
171 hemidystonia 10.0
172 infective endocarditis 10.0
173 specific language impairment 10.0
174 cerebral artery occlusion 10.0
175 cerebral degeneration 10.0
176 conversion disorder 10.0
177 psychotic disorder 10.0
178 mood disorder 10.0
179 anterior cerebral artery infarction 10.0
180 viral encephalitis 10.0
181 polycythemia 10.0
182 glioma 10.0
183 aneurysm 10.0
184 cerebral aneurysms 10.0
185 spasticity 10.0
186 glial tumor 10.0
187 amyotrophic lateral sclerosis 21 9.9 TARDBP C9orf72
188 alcohol dependence 9.9
189 atrial standstill 1 9.9
190 epidermoid cysts 9.9
191 hypercholesterolemia, familial, 1 9.9
192 multiple system atrophy 1 9.9
193 otitis media 9.9
194 panencephalitis, subacute sclerosing 9.9
195 malaria 9.9
196 leukemia, acute lymphoblastic 9.9
197 alacrima, achalasia, and mental retardation syndrome 9.9
198 chorea, childhood-onset, with psychomotor retardation 9.9
199 exanthem 9.9
200 ptosis 9.9
201 asymptomatic neurosyphilis 9.9
202 lymphocytic leukemia 9.9
203 pertussis 9.9
204 respiratory failure 9.9
205 cat-scratch disease 9.9
206 cortical blindness 9.9
207 leukemia 9.9
208 locked-in syndrome 9.9
209 quadriplegia 9.9
210 choreatic disease 9.9
211 dilated cardiomyopathy 9.9
212 transient global amnesia 9.9
213 diarrhea 9.9
214 hepatic encephalopathy 9.9
215 personality disorder 9.9
216 alcohol use disorder 9.9
217 cerebral palsy 9.9
218 cerebellar disease 9.9
219 demyelinating disease 9.9
220 purpura 9.9
221 articulation disorder 9.9
222 hyperglycemia 9.9
223 paraplegia 9.9
224 acute disseminated encephalomyelitis 9.9
225 eating disorder 9.9
226 pulmonary embolism 9.9
227 pathologic nystagmus 9.9
228 48,xyyy 9.9
229 autoimmune encephalitis 9.9
230 congenital hydrocephalus 9.9
231 elective mutism 9.9
232 limbic encephalitis 9.9
233 mast cell activation syndrome 9.9
234 neurosyphilis 9.9
235 tuberculous meningitis 9.9
236 dementia - subcortical 9.9
237 inclusion body myositis 9.9 TARDBP MAPT APP APOE
238 specific developmental disorder 9.8 PSEN1 GRN FOXP2
239 anisocoria 9.7
240 atherosclerosis susceptibility 9.7
241 autoimmune disease 9.7
242 bladder cancer 9.7
243 colorectal cancer 9.7
244 deafness, unilateral 9.7
245 erythroleukemia, familial 9.7
246 hair whorl 9.7
247 hashimoto thyroiditis 9.7
248 huntington disease 9.7
249 attention deficit-hyperactivity disorder 9.7
250 klippel-trenaunay-weber syndrome 9.7
251 medulloblastoma 9.7
252 ocular dominance 9.7
253 obsessive-compulsive disorder 9.7
254 ovarian cancer 9.7
255 nephrolithiasis, calcium oxalate 9.7
256 papillomatosis, confluent and reticulated 9.7
257 parkinson disease, late-onset 9.7
258 strabismus 9.7
259 temporal arteritis 9.7
260 thrombophilia due to thrombin defect 9.7
261 down syndrome 9.7
262 takayasu arteritis 9.7
263 hyperlexia 9.7
264 polycythemia vera 9.7
265 rolandic epilepsy, mental retardation, and speech dyspraxia, x-linked 9.7
266 mental retardation, x-linked, syndromic, houge type 9.7
267 mitochondrial myopathy, infantile, transient 9.7
268 kearns-sayre syndrome 9.7
269 helicobacter pylori infection 9.7
270 malignant atrophic papulosis 9.7
271 astigmatism 9.7
272 macular degeneration, age-related, 1 9.7
273 apraxia of eyelid opening 9.7
274 homocysteinemia 9.7
275 intervertebral disc disease 9.7
276 orthostatic intolerance 9.7
277 late-onset retinal degeneration 9.7
278 parkinson disease 8, autosomal dominant 9.7
279 ovarian hyperstimulation syndrome 9.7
280 myocardial infarction 2 9.7
281 granulomatosis with polyangiitis 9.7
282 aplastic anemia 9.7
283 human immunodeficiency virus type 1 9.7
284 west nile virus 9.7
285 cavitary optic disc anomalies 9.7
286 kawasaki disease 9.7
287 diabetes mellitus, ketosis-prone 9.7
288 gastric cancer 9.7
289 myelodysplastic syndrome 9.7
290 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.7
291 immunodeficiency, common variable, 10 9.7
292 atrial fibrillation, familial, 15 9.7
293 hydrops, lactic acidosis, and sideroblastic anemia 9.7
294 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.7
295 angina pectoris 9.7
296 pulmonary hypertension 9.7
297 adrenal cortical carcinoma 9.7
298 tick-borne encephalitis 9.7
299 epidemic typhus 9.7
300 lennox-gastaut syndrome 9.7
301 non-syndromic x-linked intellectual disability 9.7
302 focal dystonia 9.7
303 sleep apnea 9.7
304 follicular lymphoma 9.7
305 pervasive developmental disorder 9.7
306 marantic endocarditis 9.7
307 autotopagnosia 9.7
308 color agnosia 9.7
309 pain agnosia 9.7
310 tactile agnosia 9.7
311 familial hemiplegic migraine 9.7
312 atrial fibrillation 9.7
313 basal ganglia calcification 9.7
314 cardiac arrest 9.7
315 mastoiditis 9.7
316 thrombosis 9.7
317 chronic myelomonocytic leukemia 9.7
318 sensorineural hearing loss 9.7
319 cysticercosis 9.7
320 mumps 9.7
321 chronic meningitis 9.7
322 suppression amblyopia 9.7
323 amblyopia 9.7
324 bacterial infectious disease 9.7
325 common cold 9.7
326 thrombotic thrombocytopenic purpura 9.7
327 intracranial aneurysm 9.7
328 brucellosis 9.7
329 disseminated intravascular coagulation 9.7
330 cerebral arteritis 9.7
331 pulmonary edema 9.7
332 suppurative otitis media 9.7
333 lyme disease 9.7
334 nephrotic syndrome 9.7
335 hemosiderosis 9.7
336 aseptic meningitis 9.7
337 goiter 9.7
338 pulsating exophthalmos 9.7
339 pathological gambling 9.7
340 bell's palsy 9.7
341 hepatic coma 9.7
342 pseudobulbar palsy 9.7
343 guillain-barre syndrome 9.7
344 carotid stenosis 9.7
345 neurosarcoidosis 9.7
346 childhood disintegrative disease 9.7
347 chronic purulent otitis media 9.7
348 avoidant personality disorder 9.7
349 thrombocytopenia 9.7
350 endogenous depression 9.7
351 lymphadenitis 9.7
352 pneumothorax 9.7
353 heart septal defect 9.7
354 vascular disease 9.7
355 mononeuritis multiplex 9.7
356 atrial heart septal defect 9.7
357 encephalomalacia 9.7
358 hyperostosis 9.7
359 post-traumatic stress disorder 9.7
360 intestinal perforation 9.7
361 essential thrombocythemia 9.7
362 basilar artery insufficiency 9.7
363 arteriosclerosis 9.7
364 kernicterus 9.7
365 wernicke encephalopathy 9.7
366 protein s deficiency 9.7
367 thrombophilia 9.7
368 hereditary spastic paraplegia 9.7
369 acute interstitial pneumonia 9.7
370 anuria 9.7
371 substance abuse 9.7
372 acute kidney failure 9.7
373 grade iii astrocytoma 9.7
374 oligodendroglioma 9.7
375 germinoma 9.7
376 cerebritis 9.7
377 pancreatic adenocarcinoma 9.7
378 liver disease 9.7
379 syphilis 9.7
380 cerebellar astrocytoma 9.7
381 neurotic disorder 9.7
382 sleep disorder 9.7
383 schizoaffective disorder 9.7
384 kidney disease 9.7
385 aortic valve insufficiency 9.7
386 acute stress disorder 9.7
387 parasagittal meningioma 9.7
388 thyroiditis 9.7
389 situs inversus 9.7
390 muscular atrophy 9.7
391 bullous pemphigoid 9.7
392 measles 9.7
393 neuromyelitis optica 9.7
394 macroglobulinemia 9.7
395 homocystinuria 9.7
396 mechanical strabismus 9.7
397 exophthalmos 9.7
398 intracranial hypertension 9.7
399 bacterial meningitis 9.7
400 congenital syphilis 9.7
401 miliary tuberculosis 9.7
402 hypoglycemia 9.7
403 bap1 tumor predisposition syndrome 9.7
404 chchd10-related disorders 9.7
405 foxp2-related speech and language disorders 9.7
406 acute erythroid leukemia 9.7
407 alien hand syndrome 9.7
408 antisynthetase syndrome 9.7
409 arachnoid cysts 9.7
410 cluttering 9.7
411 hashimoto encephalopathy 9.7
412 hemiplegic migraine 9.7
413 neonatal stroke 9.7
414 neuromyelitis optica spectrum disorder 9.7
415 pseudobulbar affect 9.7
416 wallerian degeneration 9.7
417 anoxia 9.7
418 cerebral arteriosclerosis 9.7
419 cerebral beriberi 9.7
420 fainting 9.7
421 hypertonia 9.7
422 hypotonia 9.7
423 neuronal migration disorders 9.7
424 spinal cord injury 9.7
425 swallowing disorders 9.7
426 syncope 9.7
427 non-herpetic acute limbic encephalitis 9.7
428 rapidly involuting congenital hemangioma 9.7
429 rare hereditary hemochromatosis 9.7
430 argyria 9.7
431 mills syndrome 9.7
432 expressive language disorder 9.7 TARDBP PSEN1 FOXP2
433 dementia, lewy body 9.2 TARDBP PSEN1 PRNP MAPT GRN APP
434 central nervous system disease 9.1 TBK1 TARDBP PSEN1 PRNP MAPT APP
435 disease of mental health 8.8 TARDBP PSEN1 MAPT GRN GRIN2A C9orf72
436 nervous system disease 8.7 TBK1 TARDBP PSEN1 PRNP MAPT C9orf72

Graphical network of the top 20 diseases related to Aphasia:



Diseases related to Aphasia

Symptoms & Phenotypes for Aphasia

UMLS symptoms related to Aphasia:


seizures, tremor, fever, dyspnea, edema, cachexia, back pain, vertigo, pain, headache, syncope, scanning speech, cyanosis, chronic pain, sciatica, sore throat, icterus, signs and symptoms, signs and symptoms, digestive, other symbolic dysfunction, hot flushes, vertigo/dizziness, sleeplessness, other symptoms involving head and neck, swelling, mass, or lump in head and neck, aprosodia, aphasic, symptoms involving head and neck, other and unspecified speech disturbances, other speech disturbances, central nervous system signs and symptoms

MGI Mouse Phenotypes related to Aphasia:

46 (showing 7, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.14 APOE APP C9orf72 GRIN2A GRN L1CAM
2 cellular MP:0005384 10.02 APOE APP C9orf72 GRN L1CAM MAPT
3 hematopoietic system MP:0005397 9.97 APOE APP C9orf72 GRN MAPT PRNP
4 immune system MP:0005387 9.91 APOE APP C9orf72 GRN MAPT PRNP
5 integument MP:0010771 9.76 APOE APP GRIN2A L1CAM MAPT PRNP
6 nervous system MP:0003631 9.73 APOE APP C9orf72 CHMP2B GRIN2A GRN
7 no phenotypic analysis MP:0003012 9.28 APOE APP C9orf72 GRN L1CAM MAPT

Drugs & Therapeutics for Aphasia

Drugs for Aphasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 188, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carbidopa Approved Phase 4 28860-95-9 34359
2
Levodopa Approved Phase 4 59-92-7 6047
3
Memantine Approved, Investigational Phase 4 19982-08-2 4054
4
Donepezil Approved Phase 4 120014-06-4 3152
5
Citalopram Approved Phase 4 59729-33-8 2771
6
tannic acid Approved Phase 4 1401-55-4
7
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
8
Topiramate Approved Phase 4 97240-79-4 5284627
9
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
10
Atorvastatin Approved Phase 4 134523-00-5 60823
11
Miglustat Approved Phase 4 72599-27-0 51634
12
Corticosterone Experimental Phase 4 50-22-6 5753
13
1-Deoxynojirimycin Investigational Phase 4 19130-96-2 1374
14 Carbidopa, levodopa drug combination Phase 4
15 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
16 Parasympatholytics Phase 4
17 Muscarinic Antagonists Phase 4
18 Cholinergic Antagonists Phase 4
19 Anticonvulsants Phase 4
20 Sympathomimetics Phase 4
21 Cardiotonic Agents Phase 4
22 Cholinesterase Inhibitors Phase 4
23 Cholinergic Agents Phase 4
24 Excitatory Amino Acid Antagonists Phase 4
25 Excitatory Amino Acids Phase 4
26 Serotonin Uptake Inhibitors Phase 4
27 Antidepressive Agents Phase 4
28 Neurotransmitter Uptake Inhibitors Phase 4
29 Antidepressive Agents, Second-Generation Phase 4
30 Serotonin Agents Phase 4
31 Psychotropic Drugs Phase 4
32 Botulinum Toxins Phase 4
33 Lipid Regulating Agents Phase 4
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
35 Hypolipidemic Agents Phase 4
36 Anticholesteremic Agents Phase 4
37 Antimetabolites Phase 4
38 abobotulinumtoxinA Phase 4
39 Neuromuscular Agents Phase 4
40 Acetylcholine Release Inhibitors Phase 4
41 Botulinum Toxins, Type A Phase 4
42 Fluorodeoxyglucose F18 Phase 4
43 Anti-Inflammatory Agents Phase 4
44 Glycoside Hydrolase Inhibitors Phase 4
45 Cardiac Glycosides Phase 4
46 Anti-HIV Agents Phase 4
47 Hypoglycemic Agents Phase 4
48 Anti-Retroviral Agents Phase 4
49 Pharmaceutical Solutions Phase 4
50
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
51
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
52
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
53
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
54
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
55
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
56
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
57
Methylene blue Approved, Investigational Phase 3 61-73-4
58
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
59 Antilymphocyte Serum Phase 2, Phase 3
60 Gastrointestinal Agents Phase 3
61 Protective Agents Phase 3
62 Antiemetics Phase 3
63 Neuroprotective Agents Phase 3
64 HIV Protease Inhibitors Phase 3
65 glucocorticoids Phase 3
66 Hormones Phase 3
67
protease inhibitors Phase 3
68 Methylprednisolone Acetate Phase 3
69 Antineoplastic Agents, Hormonal Phase 3
70 Hormone Antagonists Phase 3
71 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
72 Prednisolone acetate Phase 3
73 BB 1101 Phase 3
74
Caffeine Approved Phase 2 58-08-2 2519
75
Galantamine Approved Phase 2 357-70-0 9651
76
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
77
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
78
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
79
Lithium carbonate Approved Phase 1, Phase 2 554-13-2
80
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
81
Bupivacaine Approved, Investigational Phase 1, Phase 2 2180-92-9, 38396-39-3 2474
82
Zinc Approved, Investigational Phase 2 7440-66-6 32051
83
Naratriptan Approved, Investigational Phase 1, Phase 2 121679-13-8, 143388-64-1 4440
84
Ketorolac Approved Phase 1, Phase 2 74103-06-3, 66635-83-4 3826
85
Levetiracetam Approved, Investigational Phase 2 102767-28-2 441341
86
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
87
Busulfan Approved, Investigational Phase 2 55-98-1 2478
88
alemtuzumab Approved, Investigational Phase 2 216503-57-0
89
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
90
Emodepside Investigational, Vet_approved Phase 1, Phase 2 155030-63-0
91
Betadex Experimental Phase 1, Phase 2 7585-39-9 320761
92 Purinergic P1 Receptor Antagonists Phase 2
93 Phosphodiesterase Inhibitors Phase 2
94 Histone Deacetylase Inhibitors Phase 1, Phase 2
95 Central Nervous System Stimulants Phase 2
96 adderall Phase 2
97 Dopamine Uptake Inhibitors Phase 2
98 N-monoacetylcystine Phase 1, Phase 2
99 Catechol O-Methyltransferase Inhibitors Phase 2
100 Catechol Phase 2
101 Antidotes Phase 1, Phase 2
102 Respiratory System Agents Phase 1, Phase 2
103 Free Radical Scavengers Phase 1, Phase 2
104 Antioxidants Phase 1, Phase 2
105 cysteine Phase 1, Phase 2
106 Expectorants Phase 1, Phase 2
107 Autonomic Agents Phase 1, Phase 2
108 Tranquilizing Agents Phase 1, Phase 2
109 Antimanic Agents Phase 1, Phase 2
110 Oxytocics Phase 2
111 leucine Phase 2
112 Anesthetics, Local Phase 1, Phase 2
113 Serotonin Receptor Agonists Phase 1, Phase 2
114 Liver Extracts Phase 1, Phase 2
115
Bilirubin Phase 1, Phase 2 635-65-4, 69853-43-6 5280352 21252250
116 Insulin, Globin Zinc Phase 2
117 insulin Phase 2
118 Cyclooxygenase Inhibitors Phase 1, Phase 2
119 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
120 Serotonin 5-HT1 Receptor Agonists Phase 1, Phase 2
121 Ketorolac Tromethamine Phase 1, Phase 2
122 Vasoconstrictor Agents Phase 1, Phase 2
123 Nootropic Agents Phase 2
124 Immunologic Factors Phase 2
125 Alkylating Agents Phase 2
126 Immunosuppressive Agents Phase 2
127 Antirheumatic Agents Phase 2
128 Antineoplastic Agents, Alkylating Phase 2
129 Antineoplastic Agents, Immunological Phase 2
130
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
131
Vitamin A Approved, Nutraceutical, Vet_approved Phase 1 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
132 Deoxyglucose Phase 1
133 Retinol palmitate Phase 1
134 retinol Phase 1
135 Antacids Phase 1
136 Anti-Ulcer Agents Phase 1
137 Keyhole-limpet hemocyanin Phase 1
138 Vaccines Phase 1
139 Antibodies Phase 1
140 Immunoglobulins Phase 1
141 Antibodies, Monoclonal Phase 1
142 Antiparasitic Agents Phase 1
143
Triamcinolone Approved, Vet_approved 124-94-7 31307
144
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
145
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
146
Mannitol Approved, Investigational 69-65-8 453 6251
147
Phenol Approved, Experimental 108-95-2 996
148
Benserazide Approved, Investigational 322-35-0
149
Cefpodoxime Approved, Vet_approved 80210-62-4, 82619-04-3 6335986
150
Dextromethorphan Approved 125-71-3 5360696 5362449
151
Quinidine Approved, Investigational 56-54-2 441074
152
Hydroxocobalamin Approved 13422-51-0 11953898 15589840
153
Tranexamic Acid Approved 1197-18-8 5526
154
Norepinephrine Approved 51-41-2 439260
155 Tangerine Approved
156
Copper Approved, Investigational 7440-50-8 27099
157
Cyanocobalamin Approved, Nutraceutical 68-19-9 44176380
158
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
159
Creatine Approved, Investigational, Nutraceutical 57-00-1 586
160
Cobalamin Experimental 13408-78-1 6857388
161 Flutemetamol Investigational 637003-10-2
162 triamcinolone acetonide
163 Triamcinolone hexacetonide
164 Triamcinolone diacetate
165 Chlorpheniramine, phenylpropanolamine drug combination
166 Vecuronium Bromide 50700-72-6
167 Ether
168 Adjuvants, Immunologic
169 Cefpodoxime proxetil
170 Quinidine gluconate
171 Vitamins
172 Vitamin B 12
173 Vitamin B12
174 Calciferol
175 Antipsychotic Agents
176 Radiation-Protective Agents
177 Anti-Bacterial Agents
178 Antibiotics, Antitubercular
179 polysaccharide-K
180 interferons
181 Interferon Inducers
182 Dopamine agonists
183 Radiopharmaceuticals
184 Serotonin and Noradrenaline Reuptake Inhibitors
185 Venlafaxine Hydrochloride
186 Complement System Proteins
187 Fibrinolytic Agents
188 Tissue Plasminogen Activator

Interventional clinical trials:

(showing 394, show less)
# Name Status NCT ID Phase Drugs
1 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Unknown status NCT00196703 Phase 4 memantine
2 Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction Unknown status NCT02386475 Phase 4 citalopram;sinemet plus
3 Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Aphasia) Completed NCT00102869 Phase 4 levodopa
4 Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial. Completed NCT00196690 Phase 4 Donepezil
5 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Completed NCT00640198 Phase 4 memantine;memantine;placebo
6 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
7 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
8 A Randomized, Pilot Study to Evaluate the Tolerability of OnabotulinumtoxinA Plus Topiramate vs. OnabotulinumtoxinA Plus Placebo and Long Term Effect of Treatment on Cognitive Efficiency and Continuation of Care Completed NCT01700387 Phase 4 onabotulinumtoxinA;Topiramate;Placebo
9 Effects of Early Atorvastatin Treatment During the Acute Phase of Stroke on Immunoinflammatory Markers and Outcome in Patients With Acute Ischemic Stroke Classified as LAAS According TOAST Classification Completed NCT02225834 Phase 4 Atorvastatin
10 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
11 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
12 A Single Arm Uncontrolled 12 Months Clinical Study to Evaluate the Safety and Efficacy of Miglustat (Zavesca) for the Treatment of Niemann Pick Type C Disease (NPC) in Chinese Subjects Not yet recruiting NCT03910621 Phase 4 Miglustat
13 Randomized, Double Blind, Placebo Controlled, Two Parallel Group Study to Evaluate the Efficacy and Safety of Piracetam, 12 g Intravenous (IV) Infusion Within 7 Hour (h) Post Stroke Onset, Followed by 12 g/d for 4 Weeks (IV Ampoules, Oral Solution) and 4.8 g/d for 8 Weeks (Tablets) in Adult Subjects With an Acute Ischemic Middle Cerebral Artery Stroke Terminated NCT01883011 Phase 4 Piracetam
14 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
15 COGNITIVE - Comparison of Cognitive Function After Sevoflurane or Propofol Anesthesia for Open-heart Operations Withdrawn NCT00541918 Phase 4 Diprivan (propofol, Astra Zeneca);Sevorane (sevoflurane, Abbott)
16 Improvement of Aphasia After Stroke by Intensive Training and Transcranial Direct Current Stimulation Unknown status NCT00822068 Phase 2, Phase 3
17 Effects of Repetitive Magnetic Transcranial Stimulation of Low Frequency on Speech Production in Patients With Non-fluent Aphasia Post-ischemic Stroke Unknown status NCT02241213 Phase 3
18 Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
19 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
20 A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
21 An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
22 Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
23 Behavioral and Neural Correlates of Melodic-Intonation-Therapy (MIT) and Speech-Repetition-Therapy (SRT) for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
24 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Recruiting NCT03682185 Phase 3
25 Effects of Intraoperative Local Steroid Utilization in a Single-Level Minimally Invasive Transforaminal Lumbar Interbody Fusion Active, not recruiting NCT03308084 Phase 3 Methylprednisolone;Dexamethasone
26 A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
27 Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
28 A Phase 2b/3 Open-label Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 Disease Previously Treated Under Protocol VTS301 Not yet recruiting NCT03879655 Phase 2, Phase 3 VTS-270
29 Multicenter Study of Non-invasive Repetitive Paraorbital Alternating Current Stimulation of the Brain: Therapy for Aphasy Terminated NCT01277575 Phase 3
30 An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Terminated NCT02245568 Phase 3 TRx0237
31 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS) Unknown status NCT01924702 Phase 2
32 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Unknown status NCT01221779 Phase 2
33 A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
34 Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD) Unknown status NCT03022968 Phase 2 [18F]T807 PET
35 Effectiveness of Rehabilitation (Phasic Alerting and Visual Spatial Scanning Training) on the Recovery of Patients Post Right Stroke With Unilateral Spatial Neglect: Using Functional Imaging PET and Standardized Neurobehavioral and Functional Tests Unknown status NCT00305513 Phase 2
36 Transcranial Direct Current Stimulation and Aphasia Treatment Outcomes Completed NCT01686373 Phase 2
37 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
38 Effect Of Verb Network Strengthening Treatment on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
39 Psychosocial Wellbeing Following Stroke: Developing and Testing a Psychosocial Nursing Intervention for Primary Care Completed NCT01912014 Phase 1, Phase 2
40 A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls. Completed NCT01890343 Phase 2 florbetapir 18F;18F-FDG
41 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Completed NCT02676843 Phase 2 18F-AV-1451
42 Transcranial Direct Current Stimulation and Melodic Intonation Therapy Combined With Dextroamphetamine in Chronic Stroke Patients With Non-fluent Aphasia; Safety and Efficacy Phase Completed NCT02514044 Phase 2 Dexedrine;Placebo
43 An Open Pilot Study to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Pick's Disease/Frontotemporal Dementia /Pick Complex Completed NCT00416169 Phase 2 galantamine hydrobromide
44 Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Completed NCT01937013 Phase 2 Intranasal oxytocin;Saline Nasal Mist
45 A Feasibility Trial to Evaluate the MindFrame System in the Recanalization of Occluded Vessels in Patients Experiencing an Ischemic Stroke Completed NCT00810095 Phase 2
46 Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability o